Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin hepatic arterial infusion versus sorafenib for BCLC stage C hepatocellular carcinoma
ChiCTR2000034757Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of idarubicin and sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: overall survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
idarubicinsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000034757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034757.